（图片来源：上市公司公告） 从行业分布来看，近期筹划赴港上市的A股公司覆盖电子、机械设备、医药生物、食品饮料、化工、传媒等多个领 域。其中，电子行业企业最为集中，华勤技术、芯海科技、露笑科技、极米科技、晶合集成、普源精电等均计划赴港 上市；医药生物领域有科兴制药、可孚医疗两家公司披露相关计划。此外，计算机行业的卓创资讯与万兴科技、传媒 行业的天下秀、食品饮料行业的天味食品、化工行业的美锦能源等也纷纷加入赴港上市行列。 8月以来，A股公司赴港上市步伐明显加快。 据不完全统计，已有近20家A股上市公司宣布拟筹划赴港上市，立讯精密、胜宏科技、军信股份、星环科技等企业已 正式向港交所递交H股发行上市申请。这些企业中不乏细分行业头部企业，如立讯精密、胜宏科技的A股总市值均已 突破千亿元。 8月24日晚，格林美发布公告称，董事会同意公司发行H股股票，并在港交所主板挂牌上市。此前，华勤技术、科兴制 药等A股上市公司于8月22日晚间披露了赴港上市计划。企业普遍表示，拓展国际化战略、优化海外业务布局、提升品 牌知名度、增强境外融资能力及综合竞争力是赴港上市的主要动因。 8月以来，A股公司赴港上市步伐明显加快。 有行业分析师表示 ...

Core Insights - The company reported a significant increase in revenue and net profit for the first half of the year, with revenue reaching 700.46 million yuan and net profit at 80.34 million yuan, marking a year-on-year growth of 576.45% [1] - The company is positioning itself as an innovative multinational pharmaceutical enterprise through its focus on research and development and international expansion [1] Innovation and R&D - The company has established a robust innovation pipeline based on its recombinant protein drug technology platform, focusing on high-value clinical pipelines and antibody drug development technology [2] - The company is developing several new drugs, including GB05 for respiratory syncytial virus (RSV) and GB18 for cancer cachexia, with promising clinical trial results [2][3] - The GB12 project targets specific dermatitis with a dual-blocking mechanism, showing significant advantages over existing treatments, indicating a favorable competitive landscape [3] - The company is also advancing the GB24 project, which addresses intestinal fibrosis in inflammatory bowel disease (IBD) patients, enhancing its competitive edge in gastrointestinal diseases [4] International Expansion - The company has made significant strides in its international commercialization strategy, establishing a marketing network covering over 70 countries and regions [5][6] - The company has successfully registered 18 products for overseas commercialization and received approvals in multiple countries, including the EU [6] - The introduction of high-end complex formulations, such as albumin paclitaxel, marks a transition to a new phase of international expansion, broadening the product portfolio [6] Strategic Positioning - The company is recognized for its innovative capabilities and has been actively participating in international academic events, enhancing its image as an innovative multinational biopharmaceutical enterprise [4][7] - The strategic focus on both innovation and internationalization is expected to drive sustainable growth and establish a positive image for Chinese enterprises in the global market [5][7]

本报讯 （记者王僖）8月22日晚，科兴生物制药股份有限公司（以下简称"科兴制药"）发布2025年半年 度报告。报告期内，公司实现营业收入7亿元；归属于上市公司股东的净利润8034.45万元，同比大幅增 长576.45%。 国内市场方面，公司深化区域精细化管理，拓展电商渠道，常乐康、赛若金等产品入驻京东、阿里健康 等平台，电商收入同比增长约90%。产业化建设同步发力，预充式生产线2号线投产且产能爬坡超预 期。 科兴制药有关人士表示，在政策支持、技术创新与全球化战略的共同驱动下，医药行业加速向创新驱动 转型，且随着我国对创新药支持力度的加强，创新成果不断兑现，创新药将进入新的快速发展期。公司 也将聚焦做精做强主业，外抓市场，内抓管理，不断进行创新突破，持续推进"降本增效"，实现盈利能 力稳步提升。 （编辑 何帆） 作为创新型国际化生物制药企业，科兴制药依托重组蛋白、抗体药物等先进技术平台，聚焦抗病毒、肿 瘤、免疫等领域。上半年研发创新成果凸显，不仅获得GB18注射液中国和美国的药物临床试验批准通 知书、干扰素α1b吸入溶液美国临床试验批准通知书，还持续推进长效生长激素等项目I期临床，以及聚 乙二醇化人粒细胞刺激因 ...